🥝GuideKiwi
Free Guide

Learn About Medicare Coverage for Spravato

What Is Spravato and How Does It Work? Spravato is the brand name for esketamine, a medication that the U.S. Food and Drug Administration (FDA) approved in M...

GuideKiwi Editorial Team·

What Is Spravato and How Does It Work?

Spravato is the brand name for esketamine, a medication that the U.S. Food and Drug Administration (FDA) approved in March 2019. It represents a relatively new treatment option for people dealing with treatment-resistant depression (TRD). Esketamine is a form of ketamine, a medication that has been used in anesthesia and pain management for decades, but Spravato is specifically designed and dosed for treating depression in a controlled way.

The medication works differently than traditional antidepressants. While many common antidepressants affect chemicals like serotonin or norepinephrine, Spravato works on a different brain chemical called glutamate. This different mechanism of action may help people whose depression has not responded to standard antidepressant medications. Research suggests that Spravato can begin working faster than traditional antidepressants—some people report improvements within hours or days rather than weeks.

Spravato comes as a nasal spray that people self-administer under medical supervision. The medication is delivered through the nose rather than by injection or pill. Each treatment session involves the patient using the nasal spray in a healthcare setting where medical staff can monitor them. The typical dosing starts at 56 mg and may increase to 84 mg, depending on how the person responds and tolerates the medication.

The treatment schedule is structured in phases. During the induction phase, which typically lasts two to four weeks, patients usually receive treatment twice weekly. After that, the maintenance phase involves less frequent visits—typically once weekly or once every two weeks, depending on the individual's response. This structure allows doctors to monitor how well the medication is working and adjust the schedule as needed.

Practical Takeaway: Understanding that Spravato is a newer depression treatment that works through a different mechanism than older antidepressants can help you have informed conversations with healthcare providers about whether this medication might be discussed as an option for your situation.

What Is Treatment-Resistant Depression and Who Might Benefit?

Treatment-resistant depression (TRD) is depression that does not improve adequately after trying at least two different antidepressant medications at effective doses for sufficient periods of time. The FDA has defined TRD specifically as depression that has not responded well to at least two separate antidepressant treatments. When someone has tried various medications and therapy approaches without meaningful improvement, they may be dealing with what doctors classify as TRD.

Spravato is specifically approved by the FDA for adults with TRD. This means the medication has been studied and shown to have clinical benefits for this particular group. Research indicates that for some people with TRD, Spravato can reduce depression symptoms more effectively than continuing to try additional traditional antidepressants. Studies published in medical journals have shown that many people using Spravato experienced meaningful improvements in their depression scores within days of starting treatment.

Spravato is also approved for treating major depressive disorder in adults who are experiencing acute suicidal thoughts or behaviors. For people in acute crisis, the faster-acting nature of Spravato may provide important benefits. The FDA recognized that the rapid onset of action could be particularly valuable when someone needs prompt symptom relief during a mental health emergency. This approval came after clinical trials showed that Spravato reduced suicidal thoughts more quickly than waiting for traditional antidepressants to take effect.

Not everyone with depression will use Spravato. It is typically considered after other treatments have been tried or when someone is in crisis and needs faster symptom relief. Doctors consider factors like the person's medical history, other medications they take, their ability to access regular treatment appointments, and whether they have conditions that might make Spravato unsuitable. Some medical conditions, like uncontrolled high blood pressure or certain heart rhythm problems, may make Spravato inappropriate for certain individuals.

Practical Takeaway: If you or someone you know has tried multiple antidepressants without improvement, understanding that treatment-resistant depression is a recognized medical condition for which specific medications like Spravato exist may be useful information to bring to healthcare provider conversations.

Medicare Coverage and Plan Types

Medicare is the federal health insurance program primarily for people age 65 and older, though some younger people with disabilities or specific conditions may also qualify. Medicare has different parts that cover different services. Understanding which Medicare plan types cover Spravato requires knowing a bit about how Medicare is structured.

Medicare Part B covers outpatient medications and medical services provided in office or clinic settings. Since Spravato is administered in a healthcare provider's office or approved clinic under medical supervision, the administration and monitoring typically falls under Part B coverage. This means that people with Medicare Part B coverage may have the medication and administration covered, though they would typically pay their Part B cost-sharing amounts (such as coinsurance or copayments).

Many people with Medicare also have supplemental insurance (sometimes called Medigap policies) or are enrolled in Medicare Advantage plans (Part C), which are alternative ways to receive Medicare benefits through private insurance companies. These plans may have different coverage rules and cost-sharing structures than Original Medicare. Some Medicare Advantage plans may cover Spravato, while others may require prior authorization or may not cover it at all. The specific coverage depends on the individual plan.

Coverage information can vary significantly based on which specific Medicare plan someone has. Original Medicare (Parts A and B) generally covers FDA-approved medications when administered in medical settings, but the actual costs to the patient depend on factors like whether they have met their deductible and what their coinsurance amounts are. For people in Medicare Advantage plans, the coverage and costs depend entirely on that plan's specific formulary and rules.

The 2024 Medicare Part B coinsurance typically requires patients to pay 20% of the approved amount for outpatient services after meeting the annual deductible. However, these percentages and deductibles can change annually. Additionally, once someone reaches the Part B out-of-pocket maximum in a given year, Medicare covers the remaining costs at 100% for the rest of that calendar year.

Practical Takeaway: Your specific Medicare plan type determines how Spravato coverage works for you, so checking your plan documents or contacting your plan directly can provide concrete information about your likely costs and coverage rules.

How to Understand Your Out-of-Pocket Costs

Understanding the costs associated with Spravato treatment under Medicare requires looking at several different expenses. The medication itself, the administration and monitoring services, and any necessary additional visits all have separate cost components. Medicare separates these costs in its payment structure, and your costs will depend on factors specific to your plan and your use of services that year.

Under Original Medicare Part B, you typically pay coinsurance for outpatient services. This means you pay a percentage of the Medicare-approved amount, which is usually 20% after you have met your annual Part B deductible. Each Spravato treatment session involves both the medication cost and the professional services cost (the provider's time for administration and monitoring). Both of these components are subject to the coinsurance, though the exact amounts depend on what Medicare approves as reasonable charges for these services in your geographic area.

The number of treatment sessions significantly impacts total costs. During the induction phase, which involves more frequent visits, costs accumulate more quickly. If you receive treatment twice weekly for four weeks, that is eight sessions in that month alone. If each session costs $500 in approved charges (a hypothetical example), and you pay 20% coinsurance, that would be $100 per session, or $800 for the month. Costs decrease during the maintenance phase when sessions become weekly or less frequent. Calculating your likely costs requires understanding both the typical frequency of treatments and the Medicare-approved charges in your area.

Some people may have other insurance coverage that affects their costs. If you have a Medigap supplemental policy, it may cover some or all of your coinsurance costs, potentially lowering your out-of-pocket expenses significantly. If you have a Medicare Advantage plan, your costs work differently—you may have copayments rather than coinsurance, and your costs may vary based on whether you stay in-network. Knowing your specific plan details is essential for estimating actual costs.

The manufacturer of Spravato, Janssen Pharmaceuticals, offers a patient support program that may help with certain costs. These programs sometimes provide financial assistance for medication costs or copayment support, though the specifics and eligibility

🥝

More guides on the way

Browse our full collection of free guides on topics that matter.

Browse All Guides →